publication date: Dec. 5, 2014

Varmus’s 2016 Bypass Budget Seeks “Modest” Increase of $823 Million

 

NCI has published the bypass budget for the fiscal year 2016, asking for $5.754 billion, an $823 million increase over the estimated budget of $4.931 billion.

“As a measure of how modest this funding recommendation is, consider the following: If the NCI’s annual budget had kept pace with inflation in the cost of biomedical research since fiscal year 2003, NCI cancer research funding would total $6.76 billion for fiscal year 2016,” the document states.

“Thus, the $5.75 billion recommended in the table that follows is $1 billion below the amount the NCI would have received if the budget had merely kept pace with inflation. In other words, a budget of $5.75 billion restores only 41 percent of the funding required for the NCI to recover its losses due to inflation.”

The 63-page document is posted here.

NCI directors have the unique authority to submit a summary of scientific opportunities and funding recommendations directly to the White House, bypassing review by the NIH director and the HHS Secretary. Created by the National Cancer Act of 1971, the bypass budget has been a part of the political landscape since 1974.

However, no bypass budget was produced for the fiscal years 2014 and 2015. It now appears unlikely that these documents will be produced.

Peter Garrett, a spokesman from NCI, reiterated that the institute was focused on sequestration (The Cancer Letter, Oct. 10).

“The FY 2012 and 2013 bypass budgets required extensive involvement from the NCI director, the two chief deputies and the … Continue reading 40-45 Varmus’s 2016 Bypass Budget Seeks “Modest” Increase of $823 Million

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.